Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915685 | 1.00 | CCR5 (0.56) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL14168719 | 0.92 | CCR5 (0.49) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL14155704 | 0.86 | CCR5 (0.62) | CCR5 | |
| SCHEMBL12530439 | 0.84 | ALDH1A1 (0.44) | CCR5OPRM1KCNH2 | |
| SCHEMBL4131541 | 0.81 | CCR5 (0.52) | CCR5KCNH2 | |
| SCHEMBL12946593 | 0.80 | CCR5 (0.48) | CCR5KCNH2 | |
| SCHEMBL4939107 | 0.79 | CCR5 (0.60) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL3873705 | 0.79 | CCR5 (0.60) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL13915693 | 0.79 | CCR5 (0.60) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL29904327 | 0.78 | CCR5 (0.49) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556899-B2 | Method for preparing Maraviroc | SCI PHARMTECH, INC. (TW) | 2020-02-11 | — | — | US | disclosed |
| US-20190248782-A1 | METHOD FOR PREPARING MARAVIROC | SCI PHARMTECH, INC. (TW) | 2019-08-15 | — | — | US | disclosed |
| WO-2014173375-A1 | A PROCESS FOR THE SYNTHESIS OF MARAVIROC | ZENTIVA, K.S. (CZ) | 2014-10-30 | — | — | WO | disclosed |
| CN-102766141-B | Preparation method of 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo (3.2.1)octane | WENZHOU MEDICAL COLLEGE | 2014-09-03 | — | — | CN | disclosed |
| US-8779143-B2 | Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form | HETERO RESEARCH FOUNDATION (IN) | 2014-07-15 | — | — | US | disclosed |
| EP-1910573-B1 | METHODS FOR REDUCING VIRAL LOAD IN HIV-1-INFECTED PATIENTS | CYTODYN INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130211091-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | HETERO RESEARCH FOUNDATION (IN) | 2013-08-15 | — | — | US | disclosed |
| EP-2611446-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | Hetero Research Foundation (IN) | 2013-07-10 | — | — | EP | disclosed |
| EP-1990341-B1 | Triazolyl tropane derivatives as CCR5 modulators | PFIZER (US) | 2013-01-23 | — | — | EP | disclosed |
| CN-102766141-A | Preparation method of 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo (3.2.1)octane | WENZHOU MEDICAL COLLEGE | 2012-11-07 | — | — | CN | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1625120-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099178-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| US-20040067977-A1 | Tropane derivatives useful in therapy | PFIZER, INC. | 2004-04-08 | — | — | US | disclosed |
| EP-1284974-B1 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-6667314-B2 | For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis | PFIZER, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20020013337-A1 | Tropane derivatives useful in therapy | PHIVCO-1 LLC | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | CCR5 1/4885CYP3A4 664/4885ADRA2A 82/4885 |
| US-20020013337-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | CCR5 385/4885CYP3A4 246/4885ADRA2A 9/4885 |
| US-20040067977-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | CCR5 385/4885CYP3A4 246/4885ADRA2A 9/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | CCR5 1/4885CYP3A4 294/4885ADRA2A 106/4885 |
| US-10556899-B2 | Method for preparing Maraviroc | CYP3A43, NAT10, CYP3A5 | CCR5 387/4885CYP3A4 5/4885ADRA2A 738/4885 |
| US-20190248782-A1 | METHOD FOR PREPARING MARAVIROC | CYP3A43, NAT10, CYP3A5 | CCR5 387/4885CYP3A4 5/4885ADRA2A 738/4885 |
| US-20130211091-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | PNP, TYMP, SAMHD1 | CCR5 63/4885CYP3A4 32/4885ADRA2A 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.